Last reviewed · How we verify
BMS-986205
BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity. Used for Acute coronary syndrome, Chronic kidney disease.
At a glance
| Generic name | BMS-986205 |
|---|---|
| Also known as | Linrodostat |
| Sponsor | Bristol-Myers Squibb |
| Drug class | NLRP3 inflammasome inhibitor |
| Target | NLRP3 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The NLRP3 inflammasome is a multi-protein complex that activates caspase-1, leading to production of pro-inflammatory cytokines IL-1β and IL-18. By selectively inhibiting NLRP3, BMS-986205 dampens pathological inflammation without broadly suppressing immune function. This mechanism is relevant to inflammatory and autoinflammatory diseases where NLRP3 activation drives disease pathology.
Approved indications
- Acute coronary syndrome
- Chronic kidney disease
Common side effects
- Infection
- Elevated liver enzymes
- Gastrointestinal disorders
Key clinical trials
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer (PHASE3)
- Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment (PHASE2)
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck (PHASE2)
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (PHASE1, PHASE2)
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (PHASE1, PHASE2)
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer (PHASE1, PHASE2)
- A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |